A myristoylated cell-penetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery

Molecular Pharmaceutics

Volumn 11, Issue 2, 2014, Pages 486-495

  Youn, Pilju ^a   Chen, Yizhe ^a   Furgeson, Darin Y ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

blood brain barrier (BBB); cell penetrating peptide; neuro targeting; neurodegenerative disorders (NDDs); receptor mediated transcytosis; siRNA carrier; transferrin receptor

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CELL PENETRATING PEPTIDE; MYRISTIC ACID; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ARTICLE; ASSAY; ASTROCYTE; BRAIN CELL; CANCER CELL CULTURE; DRUG DELIVERY SYSTEM; ENCAPSULATION; FLUORESCENCE; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; KINETICS; LUCIFERASE ASSAY; MOUSE; NERVE CELL; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TRANSCYTOSIS; AMINO ACID SEQUENCE; ANIMAL; BRAIN; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; GENE THERAPY; IMMUNOHISTOCHEMISTRY; METABOLISM; NEURODEGENERATIVE DISEASES;

AMINO ACID SEQUENCE; ANIMALS; ASTROCYTES; BRAIN; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GENETIC THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MYRISTIC ACID; NEURODEGENERATIVE DISEASES; RECEPTORS, TRANSFERRIN; RNA, SMALL INTERFERING;

EID: 84893229394     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400446v     Document Type: Article

References (48)

1. Batsch, N. L.; Mittelman, M. S. World Alzheimer report 2012. Overcoming the stigma of dementia. Alzheimer's disease international. Available at: http://www.alz.co.uk/research/WorldAlzheimerReport2012.pdf (accessed March 11, 2013).
2. Thies, W.; Bleiler, L. Alzheimer's disease facts and figures Alzheimers Dement. 2011, 7, 208-244
3. Abbott, N. J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier Nat. Rev. Neurosci. 2006, 7, 41-53 (Pubitemid 41828930)
4. Pardridge, W. M. Blood-brain barrier biology and methodology J. Neurovirol. 1999, 5, 556-569 (Pubitemid 30032082)
5. Pavan, B.; Dalpiaz, A.; Ciliberti, N.; Biondi, C.; Manfredini, S.; Vertuani, S. Progress in drug delivery to the central nervous system by the prodrug approach Molecules 2008, 13, 1035-1065
6. Groothuis, D. R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery Neuro-Oncology 2000, 2, 45-59
7. Tiraboschi, P.; Hansen, L.; Thal, L.; Corey-Bloom, J. The importance of neuritic plaques and tangles to the development and evolution of AD Neurology 2004, 62, 1984-1989 (Pubitemid 38738208)
8. Braak, H.; Tredici, K. D.; Rüb, U.; de Vos, R. A.; Jansen Steur, E. N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 2003, 24, 197-211 (Pubitemid 36007810)
9. Scherzinger, E.; Sittler, A.; Schweiger, K.; Heiser, V.; Lurz, R.; Hasenbank, R.; Bates, G. P.; Lehrach, H.; Wanker, E. E. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology Proc. Natl. Acad. Sci. 1999, 96, 4604-4609 (Pubitemid 29190383)
10. Melo, A.; Monteiro, L.; Lima, R. M. F.; de Cerqueira, M. D. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives Oxid. Med. Cell. Longev. 2011, 2011, 1-14
11. Motohashi, H.; Yamamoto, M. Nrf2-Keap1 defines a physiologically important stress response mechanism Trends. Mol. Med. 2004, 10, 549-557 (Pubitemid 39433824)
12. Barnham, K. J.; Masters, C. L.; Bush, A. I. Neurodegenerative diseases and oxidative stress Nat. Rev. Drug Discovery 2004, 3, 205-214
13. Calkins, M. J.; Johnson, D. A.; Townsend, J. A.; Vargas, M. R.; Dowell, J. A.; Williamson, T. P.; Kraft, A. D.; Lee, J. M.; Li, J.; Johnson, J. A. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease Antioxid. Redox. Signal. 2009, 11, 497-508
14. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel, J. D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Gene. Dev. 1999, 13, 76-86 (Pubitemid 29045117)
15. Kobayashi, M.; Yamamoto, M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation Antioxid. Redox. Signal. 2005, 7, 385-394 (Pubitemid 40279806)
16. Layzer, J. M. M.; McCaffrey, A. P.; Tanner, A. K.; Huang, Z.; Kay, M. A.; Sullenger, B. A. In vivo activity of nuclease-resistant siRNAs RNA 2004, 10, 766-771 (Pubitemid 38529739)
17. Turner, J. J.; Jones, S. W.; Moschos, S. A.; Lindsay, M. A.; Gait, M. J. MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity Mol. Biosyst. 2006, 3, 43-50 (Pubitemid 44924958)
18. Nakajima, H.; Kubo, T.; Semi, Y.; Itakura, M.; Kuwamura, M.; Izawa, T.; Azuma, Y.-T.; Takeuchi, T. A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain J. Biotechnol. 2012, 157, 326-333
19. Chen, C.; Mei, H.; Shi, W.; Deng, J.; Zhang, B.; Guo, T.; Wang, H.; Hu, Y. EGFP-EGF1-conjugated PLGA nanoparticles for targeted delivery of siRNA into injured brain microvascular endothelial cells for efficient RNA interference PLoS One 2013, 8, e60860
20. Malmo, J.; Sandvig, A.; VaÌŠrum, K. M.; Strand, S. P. Nanoparticle mediated p-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach PLoS One 2013, 8, e54182
21. Alvarez-Erviti, L.; Seow, Y.; Yin, H. F.; Betts, C.; Lakhal, S.; Wood, M. J. A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat. Biotechnol. 2011, 29, 341-345
22. Tao, Y.; Han, J.; Dou, H. Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study J. Mater. Chem. 2012, 22, 11808-11815
23. Xia, C. F.; Zhang, Y.; Boado, R. J.; Pardridge, W. M. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology Pharm. Res. 2007, 24, 2309-2316 (Pubitemid 350060723)
24. Kuwahara, H.; Nishina, K.; Yoshida, K.; Nishina, T.; Yamamoto, M.; Saito, Y.; Piao, W.; Yoshida, M.; Mizusawa, H.; Yokota, T. Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein Mol. Ther. 2011, 19, 2213-2221
25. Wang, Y. H.; Hou, Y. W.; Lee, H. J. An intracellular delivery method for siRNA by an arginine-rich peptide J. Biochem. Biophys. Methods 2007, 70, 579-586
26. Leng, Q.; Goldgeier, L.; Zhu, J.; Cambell, P.; Ambulos, N.; Mixson, A. J. Histidine-lysine peptides as carriers of nucleic acids Drug News Perspect. 2007, 20, 77
27. Deshayes, S.; Morris, M.; Divita, G.; Heitz, F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics Cell. Mol. Life Sci. 2005, 62, 1839-1849 (Pubitemid 41188523)
28. Gupta, B.; Levchenko, T. S.; Torchilin, V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides Adv. Drug Delivery Rev. 2005, 57, 637-651 (Pubitemid 40255564)
29. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters Proc. Natl. Acad. Sci. 2000, 97, 13003
30. Kim, W. J.; Christensen, L. V.; Jo, S.; Yockman, J. W.; Jeong, J. H.; Kim, Y. H.; Kim, S. W. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma Mol. Ther. 2006, 14, 343-350 (Pubitemid 44184964)
31. Kumar, P.; Wu, H.; McBride, J. L.; Jung, K. E.; Kim, M. H.; Davidson, B. L.; Lee, S. K.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system Nature 2007, 448, 39-43 (Pubitemid 47037001)
32. Ren, Y.; Hauert, S.; Lo, J. H.; Bhatia, S. N. Identification and characterization of receptor-specific peptides for siRNA delivery ACS Nano 2012, 6, 8620-8631
33. Pham, W.; Kircher, M. F.; Weissleder, R.; Tung, C. H. Enhancing membrane permeability by fatty acylation of oligoarginine peptides ChemBioChem 2004, 5, 1148-1151 (Pubitemid 39257039)
34. Galbiati, F.; Guzzi, F.; Magee, A. I.; Milligan, G.; Parenti, M. Chemical inhibition of myristoylation of the G-protein Gi1 alpha by 2-hydroxymyristate does not interfere with its palmitoylation or membrane association. Evidence that palmitoylation, but not myristoylation, regulates membrane attachment Biochem. J. 1996, 313, 717-721
35. Nelson, A. R.; Borland, L.; Allbritton, N. L.; Sims, C. E. Myristoyl-based transport of peptides into living cells Biochemistry 2007, 46, 14771-14781 (Pubitemid 350308869)
36. Ifediba, M. A.; Medarova, Z.; Ng, S.-w.; Yang, J.; Moore, A. siRNA delivery to CNS cells using a membrane translocation peptide Bioconjugate Chem. 2010, 21, 803-806
37. Lee, J. H.; Engler, J. A.; Collawn, J. F.; Moore, B. A. Receptor mediated uptake of peptides that bind the human transferrin receptor Eur. J. Biochem. 2001, 268, 2004-2012 (Pubitemid 32852941)
38. Van Kuik-Romeijn, P.; Platenburg, G. J. Molecules for targeting compounds to various selected organs, tissues or tumor cells. U.S. Patent No. 2010/0184947 A1, 2010.
39. Gan, L.; Johnson, D. A.; Johnson, J. A. Keap1-Nrf2 activation in the presence and absence of DJ-1 Eur. J. Neurosci. 2010, 31, 967-977
40. Rouault, T. A.; Cooperman, S. Brain iron metabolism Semin. Pediatr. Neurol. 2006, 13, 142-148 (Pubitemid 44709651)
41. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol. Rev. 2002, 54, 561-587 (Pubitemid 35351196)
42. Shayan, G.; Choi, Y. S.; Shusta, E. V.; Shuler, M. L.; Lee, K. H. Murine in vitro model of the blood-brain barrier for evaluating drug transport Eur. J. Pharm. Sci. 2010, 42, 148-155
43. Wilhelm, I.; Fazakas, C.; Krizbai, I. A. In vitro models of the blood-brain barrier Acta Neurobiol. Exp. (Warsaw) 2011, 71, 113-128
44. Leroueil, P. R.; Berry, S. A.; Duthie, K.; Han, G.; Rotello, V. M.; McNerny, D. Q.; Baker, J. R.; Orr, B. G.; Banaszak Holl, M. M. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers Nano Lett. 2008, 8, 420-424 (Pubitemid 351345993)
45. Kennedy, M. T.; Pozharski, E. V.; Rakhmanova, V. A.; MacDonald, R. C. Factors governing the assembly of cationic phospholipid-DNA complexes Biophys. J. 2000, 78, 1620-1633 (Pubitemid 30141585)
46. Bartlett, D. W.; Davis, M. E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing Biotechnol. Bioeng. 2007, 97, 909-921 (Pubitemid 47051060)
47. Brown, R. C.; Morris, A. P.; O'Neil, R. G. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells Brain Res. 2007, 1130, 17-30 (Pubitemid 46053886)
48. Hanson, L. R.; Frey, W. H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease BMC Neurosci. 2008, 9, S5